GRS has developed an ecosystem to fully support the evolution of Biologics to ensure that research will translate into commercial products to improve patient outcomes. We have gone beyond the conventional boundaries of regulatory affairs and quality compliance to be able to offer support, advice and guidance at the earliest stage possible. By getting involved at ‘grass roots’ level, we can help researchers define their vision and maximise their grant funding. GRS will also provide researchers with the opportunity to go beyond the end of the grant. We have the support and expertise needed to take these ‘concept’ biologics through to development and ultimately to the patient.
Bobby Deal, Managing Director, said: “I’m delighted to be able to offer this support to the Biological Sector because I strongly believe that there is a significant missing link between research and commercialisation. GRS is now that link and with the help of our great team of professionals we can maximise the opportunities for launching biological products into the clinic. As many already know, very few biologics make it beyond the end of the grant and we want to change that. I am convinced that these new therapies will be a huge benefit not only to patient welfare and quality of life but will also help to ease the financial pressures on our healthcare systems.”
__________________________________________